By Lisa Kerner
Charlotte, N.C., Nov. 8 - MedGenesis Therapeutix Inc. closed a $3.2 million round of private equity financing.
Proceeds will be used to advance the clinical development of its lead therapeutic program and the filing of an Investigational New Drug application to begin human studies.
Located in Victoria, B.C., MedGenesis is a biopharmaceutical company focused on the development of therapeutics for the treatment of serious central nervous system disease.
| Issuer: | MedGenesis Therapeutix Inc.
|
| Issue: | Private equity financing
|
| Amount: | $3.2 million
|
| Announcement date: | Nov. 8
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
